文献速递青光眼

溶血磷脂酸与IL-6反式信号在人小梁网细胞中经YAP/TAZ和STAT3通路交互

Lysophosphatidic Acid and IL-6 Trans-signaling Interact via YAP/TAZ and STAT3 Signaling Pathways in Human Trabecular Meshwork Cells.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

研究在人小梁网细胞中探讨溶血磷脂酸(LPA)与IL6/可溶性IL6受体(sIL6R)反式信号是否经YAP/TAZ或STAT3通路交互。结果表明二者协同上调受体、信号介质、收缩机器和纤维化细胞外基质靶点,维替泊芬抑制YAP、TAZ和pSTAT3并消除上述纤维化靶点,STAT3抑制剂仅部分有效。

要点

  • LPA与IL6/sIL6R共处理协同上调YAP、TAZ、Pan-TEAD和pSTAT3等信号介质。
  • 共处理协同上调MLC2、pMLC2、ROCK1、F-actin和α-SMA等收缩机器组分。
  • 维替泊芬抑制YAP、TAZ和pSTAT3并消除纤维化靶点,STAT3抑制剂仅部分有效。

核心结论

  • LPA与IL6反式信号在人小梁网细胞中存在由YAP、TAZ和pSTAT3介导的协同交互。
  • 维替泊芬通过完全抑制这些介质,可能更有效改善LPA和/或IL6反式信号诱导的眼压升高表型。

研究设计与样本

  • 原代融合人小梁网细胞血清饥饿24小时后处理24小时。
  • 处理组包括溶剂对照、LPA(20 µM)、IL6(100 ng/mL)/sIL6R(200 ng/mL)及二者联合。
  • 部分实验加用YAP抑制剂维替泊芬(2 µM)或STAT3抑制剂(2 µM)。
  • 采用免疫细胞化学、RT-qPCR和Western blot检测受体配体、信号介质、收缩机器和细胞外基质靶点。

主要发现

  • LPA与IL6反式信号耦合过表达/激活受体与配体、糖蛋白130、IL6和自分泌运动因子。
  • 耦合过表达/激活信号介质YAP、TAZ、Pan-TEAD和磷酸化STAT3。
  • 耦合过表达/激活MLC2、磷酸化MLC2、ROCK1、丝状肌动蛋白和α-平滑肌肌动蛋白。
  • 耦合过表达/激活胶原I和IV、纤连蛋白、层粘连蛋白、富含半胱氨酸血管生成诱导剂61和结缔组织生长因子。
  • 上述效应大多超过LPA或IL6反式信号单独作用;维替泊芬抑制YAP、TAZ和pSTAT3并消除纤维化靶点,STAT3抑制剂仅部分有效。

关键数值与推荐

  • LPA使用浓度为20 µM,处理24小时。
  • IL6使用浓度为100 ng/mL,sIL6R使用浓度为200 ng/mL,处理24小时。
  • 维替泊芬使用浓度为2 µM,STAT3抑制剂使用浓度为2 µM。

临床怎么用

  • 在POAG相关小梁网纤维化模型中,LPA与IL6反式信号协同激活YAP/TAZ和STAT3促纤维化程序。
  • 维替泊芬在体外完全抑制YAP、TAZ和pSTAT3并消除纤维化靶点,STAT3抑制剂仅部分有效,提示靶向YAP/TAZ可能更有效。

局限性

  • 研究仅在人小梁网细胞体外模型中进行,未提供体内或临床数据。
  • 未报告样本量、统计P值或置信区间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lysophosphatidic acid (LPA) and soluble interleukin-6 receptor (sIL6R) are elevated in primary open angle glaucoma (POAG). LPA and IL6 modulate in response to biomechanical stimuli and converge on similar fibrotic phenotypes. Thus, we determined whether LPA and IL6 trans-signaling (IL6/sIL6R) interact via Yes-associated protein (YAP)/Transcriptional coactivator with a PDZ-binding motif (TAZ) or Signal transducer and activator of transcription 3 (STAT3) pathways in human trabecular meshwork (hTM) cells. METHODS: Confluent primary hTM cells were serum starved for 24 hours, and treated with vehicle, LPA (20 µM), IL6 (100 ng/mL)/sIL6R (200 ng/mL), or both (LPA + IL6/sIL6R) for 24 hours, with or without a YAP inhibitor (verteporfin; 2 µM) or STAT3 inhibitor (2 µM). Expression of key receptors and ligands, signaling mediators, actomyosin machinery, cell contractility, and extracellular matrix (ECM) targets of both signaling pathways was determined by immunocytochemistry, RT-qPCR, and Western blotting. RESULTS: LPA and IL6 trans-signaling coupling overexpressed/activated receptors and ligands, glycoprotein-130, IL6, and autotaxin; signaling mediators, YAP, TAZ, Pan-TEAD, and phosphorylated STAT3 (pSTAT3); actomyosin and contractile machinery components, myosin light chain 2 (MLC2), phosphorylated MLC2, rho-associated protein kinase 1, filamentous actin, and α-smooth muscle actin; and fibrotic ECM proteins, collagen I and IV, fibronectin, laminin, cysteine-rich angiogenic inducer 61, and connective tissue growth factor in hTM cells; mostly beyond LPA or IL6 trans-signaling alone. Verteporfin inhibited YAP, TAZ, and pSTAT3, with concomitant abrogation of aforementioned fibrotic targets; the STAT3 inhibitor was only partially effective. CONCLUSIONS: These data suggest synergistic crosstalk between LPA and IL6 trans-signaling, mediated by YAP, TAZ, and pSTAT3. By completely inhibiting these mediators, verteporfin may be more efficacious in ameliorating LPA and/or IL6 trans-signaling-induced ocular hypertensive phenotypes in hTM cells.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Yemanyi F, Raghunathan V. Lysophosphatidic Acid and IL-6 Trans-signaling Interact via YAP/TAZ and STAT3 Signaling Pathways in Human Trabecular Meshwork Cells. Invest Ophthalmol Vis Sci. 2020. PMID: 33216119. doi:10.1167/iovs.61.13.29

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。